Maynard Um
-
-
-
-
-
-
-
RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $215 at Stifel
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $170 at BMO Capital
-
-
-
-
-
-
-
Neurocrine presents INGREZZA data for tardive dyskinesia patients
-
-
-
-
-
-
-
Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY
-
-
-
-
-
-
-
INGREZZA shows higher treatment persistence than AUSTEDO XR in study
-
-
-
-
-
-
-
Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition
-
466,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


